Compare OVBC & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | SLGL |
|---|---|---|
| Founded | 1872 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 218.9M |
| IPO Year | 1996 | 2016 |
| Metric | OVBC | SLGL |
|---|---|---|
| Price | $46.65 | $67.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $152.50 |
| AVG Volume (30 Days) | 13.8K | ★ 32.0K |
| Earning Date | 11-03-2026 | 11-19-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.18 | $28.81 |
| 52 Week High | $51.25 | $97.97 |
| Indicator | OVBC | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 44.09 |
| Support Level | $46.54 | $60.91 |
| Resistance Level | $47.59 | $80.53 |
| Average True Range (ATR) | 0.96 | 4.34 |
| MACD | 0.13 | -0.53 |
| Stochastic Oscillator | 86.34 | 19.57 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services in Southeastern Ohio and western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers, and other standard banking products and services.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.